Setrusumab
UX143-CL301
Phase 3 mab active
Quick answer
Setrusumab for Osteogenesis Imperfecta is a Phase 3 program (mab) at Mereo BioPharma Group plc with 2 ClinicalTrials.gov record(s).
Program details
- Company
- Mereo BioPharma Group plc
- Indication
- Osteogenesis Imperfecta
- Phase
- Phase 3
- Modality
- mab
- Status
- active